A Pilot Proteomic Analysis of Huntington's Disease by Functional Capacity

被引:0
|
作者
Mcgarry, Andrew [1 ]
Moaddel, Ruin [2 ]
机构
[1] Rowan Univ, Cooper Univ Healthcare, Camden, NJ 08103 USA
[2] NIH, Biomed Res Ctr, Natl Inst Aging, Baltimore, MD 21224 USA
关键词
HD; cerebrospinal fluid; inflammation; NAD(+) metabolism; TFC score; SIRT5; NEURODEGENERATION; IMPAIRMENT; HUMANS; ROLES; GENE;
D O I
10.3390/brainsci15010076
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: The molecular biology of Huntington's Disease (HD) has grown substantially, with pathological considerations extending to genetic modifiers, epigenetic changes, transcriptomics, the proteome, and the metabolome. The metabolome and proteome are especially intriguing in that they most directly reflect the functional state of the cellular environment, which may involve some combination of pathology as well as compensation. Methods: We assessed CSF proteomics from eight participants by their functional severity (TFC range 3-13), with 47 proteins having a minimum r-value of 0.7 and nominal p-values < 0.05. Results: Our exploratory data reveal correlations between progression and several processes including inflammation, ECM homeostasis and NAD(+) metabolism. Conclusions: Consistently identified targets that correlate with phenotype or progression may have value, if validated, as enrichment tools in clinical trials and potentially as markers of therapeutic response.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Proteomic Analysis of Huntington's Disease
    Kumar, Shobhit
    Singh, Priyanka
    Sharma, Shrestha
    Ali, Javed
    Baboota, Sanjula
    Pottoo, Faheem Hyder
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2020, 21 (12) : 1218 - 1222
  • [2] Neuropsychiatric Symptoms and Functional Capacity in Huntington's Disease
    Sellers, J.
    Ridner, S.
    Claassen, D.
    NEUROTHERAPEUTICS, 2018, 15 (04) : 1196 - 1197
  • [3] Huntington's disease progression model of total functional capacity scores
    Venuto, C. S.
    Dorsey, E. R.
    Kieburtz, K. D.
    MOVEMENT DISORDERS, 2014, 29 : S218 - S218
  • [4] A Systematic Review of Neuropsychiatric Symptoms and Functional Capacity in Huntington's Disease
    Sellers, Jessie
    Ridner, Sheila H.
    Claassen, Daniel O.
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2020, 32 (02) : 109 - 124
  • [5] Predictors of functional capacity, quality of life and caregivers' burden in Huntington's disease
    Banaszkiewicz, K.
    Rudzinska, M.
    Szczudlik, A.
    MOVEMENT DISORDERS, 2009, 24 : S163 - S163
  • [6] Pilot proteomic analysis of cerebrospinal fluid in Alzheimer's disease
    McKetney, Justin
    Panyard, Daniel J.
    Johnson, Sterling C.
    Carlsson, Cynthia M.
    Engelman, Corinne D.
    Coon, Joshua J.
    PROTEOMICS CLINICAL APPLICATIONS, 2021, 15 (2-3)
  • [7] Functional analysis of the Huntington's disease (HD) gene promoter
    Coles, R
    Caswell, R
    Rubinsztein, DC
    HUMAN MOLECULAR GENETICS, 1998, 7 (05) : 791 - 800
  • [8] Effect of Pridopidine on Functional Capacity of Patients with Huntington Disease
    McGarry, Andrew
    Abler, Victor
    Auinger, Peggy
    Grachev, Igor D.
    Gandhi, Sanjay
    Papapetropoulos, Spyros
    NEUROTHERAPEUTICS, 2017, 14 (01) : 234 - 234
  • [9] Functional imaging in Huntington's disease
    Paulsen, Jane S.
    EXPERIMENTAL NEUROLOGY, 2009, 216 (02) : 272 - 277
  • [10] Minocycline in Huntington's disease: A pilot study
    Thomas, M
    Ashizawa, T
    Jankovic, J
    MOVEMENT DISORDERS, 2004, 19 (06) : 692 - 695